Golgi Neurosciences and leadXpro announce collaboration on GPR65 modulators

Milan, Italy, and Villigen, Switzerland 29th May 2024. Today, we are happy to announce our partnership with Golgi Neurosciences, a pioneering company-creator boutique dedicated to developing therapies for neurodegenerative diseases.

Together, we created significant progress with different classes of positive and negative modulators of GPR65, a proton-sensing G protein–coupled receptor (GPCR). This receptor is involved in relevant pathways in indications such as neuroinflammation, multiple sclerosis, Parkinson’s disease, fibrosis, cancer, and inflammatory bowel disease.

A key milestone in our ongoing collaboration has been the elucidation of high-resolution structures of GPR65 using Cryo-EM. This major advancement significantly enhances our ability to understand these targets and develop effective therapies.

We invite interested parties to reach out to us to discuss out-licensing opportunities and explore how we can collaborate to advance these promising therapies.

Stay tuned for more updates on our joint efforts to make a lasting impact on the treatment of these challenging conditions.